Abstract
Proviruses carrying drug-inducible Oct4, Sox2, Klf4 and c-Myc used to derive 'primary' induced pluripotent stem (iPS) cells were segregated through germline transmission, generating mice and cells carrying subsets of the reprogramming factors. Drug treatment produced 'secondary' iPS cells only when the missing factor was introduced. This approach creates a defined system for studying reprogramming mechanisms and allows screening of genetically homogeneous cells for compounds that can replace any transcription factor required for iPS cell derivation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jaenisch, R. & Young, R. Cell 132, 567–582 (2008).
Takahashi, K. & Yamanaka, S. Cell 126, 663–676 (2006).
Wernig, M. et al. Nature 448, 318–324 (2007).
Takahashi, K. et al. Cell 131, 861–872 (2007).
Hanna, J. et al. Science 318, 1920–1923 (2007).
Shi, Y. et al. Cell Stem Cell 3, 568–574 (2008).
Marson, A. et al. Cell Stem Cell 3, 132–135 (2008).
Huangfu, D. et al. Nat. Biotechnol. 26, 1269–1275 (2008).
Wernig, M. et al. Nat. Biotechnol. 26, 916–924 (2008).
Hanna, J. et al. Cell 133, 250–264 (2008).
Wernig, M. et al. Cell Stem Cell 2, 10–12 (2008).
Nakagawa, M. et al. Nat. Biotechnol. 26, 101–106 (2008).
Acknowledgements
We thank G. Bell, R. Flannery and members of the Jaenisch lab for assistance and comments. R.J. is supported by grants from the National Institutes of Health: 5-RO1-HDO45022, 5-R37-CA084198 and 5-RO1-CA087869. J.H. is a Novartis Fellow by the Helen Hay Whitney Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J. is an advisor to Stemgent.
Supplementary information
Supplementary Fig. 1
Supplementary Methods, Figures 1–9, Tables 1–3 (PDF 764 kb)
Rights and permissions
About this article
Cite this article
Markoulaki, S., Hanna, J., Beard, C. et al. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat Biotechnol 27, 169–171 (2009). https://doi.org/10.1038/nbt.1520
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1520
This article is cited by
-
AAV vector-mediated in vivo reprogramming into pluripotency
Nature Communications (2018)
-
Defined three-dimensional microenvironments boost induction of pluripotency
Nature Materials (2016)
-
Improvement in Mouse iPSC Induction by Rab32 Reveals the Importance of Lipid Metabolism during Reprogramming
Scientific Reports (2015)
-
Direct conversion of human amniotic cells into endothelial cells without transitioning through a pluripotent state
Nature Protocols (2015)
-
In vivo reprogrammed pluripotent stem cells from teratomas share analogous properties with their in vitro counterparts
Scientific Reports (2015)